Article de revue
Overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis
The mosquito-borne Japanese encephalitis virus causes an estimated 50,000 cases in Asia, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. IXIARO® (Intercell AG, Vienna, Austria), an inactivated, Vero cell-derived vaccine against Japanese encephalitis was introduced in 2009. The vaccine is highly immunogenic, showing significantly higher geometric mean antibody titers compared with previous, mouse brain-derived vaccines. Postmarketing studies have confirmed the excellent safety profile. Studies on children aged 2 months to 18 years have been published. Based on these data, positive opinion from the EMA for vaccination of children has recently been given. Since a safe and effective vaccine against Japanese encephalitis is now available, outdated guidelines and recommendations have to be revised: travelers to rural areas of Asia should generally be recommended vaccination.
Auteurs
Langues
- Anglais
Année de publication
2013
Journal
Expert Rev Vaccines.
Volume
Ahead of Print
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Encéphalite japonaise
Pays
- Japon
